List of publications by EMBRN members
Login in for more content
You can get access to this area and its contents if you are a member of EMBRN. A membership with EMBRN provides you with access to EMBRN experimental protocols, recent papers from the EMBRN lab and an updated member list.
To become a member with EMBRN, please fill out the membership form.
Summary B lymphocytes are among the cell types whose effector functions are modulated by mast cells (MCs). The B/MC crosstalk emerged in several pathological settings, notably the colon of inflammatory bowel disease (IBD) patients is a privileged site in which MCs and IgA+ cells physically interact. Herein, by inducing conditional
Summary Unsupervised mapping of leukocyte surface markers identified a granulocytic COVID-19 signature comprising eosinophil and basophil CRTH2 downregulation, increased counts of CD15+CD16+ neutrophils, and decreased granulocytic CD11b expression, while PDL1 checkpoint expression in basophils and eosinophils was associated with severity. Citation A granulocytic signature identifies COVID-19 and its severity. Vitte
AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)
Summary Elevated serum IgE levels are associated with allergic disorders, parasitosis and specific immunologic abnormalities. In addition, pidemiological and mechanistic evidence indicates an association between IgE-mediated immune surveillance and protection from tumour growth. Intriguingly, recent studies reveal a correlation between IgE deficiency and increased malignancy risk. This is the first
A rational roadmap for SARS-CoV-2/COVID-19pharmacotherapeutic research and development: IUPHARReview 29
Summary In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targetting key host and viral targets in the mid-term, by first screening